International Journal of Infectious Diseases最新文献

{"title":"Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.","authors":"Sirapoom Niamsanit, Phanthila Sitthikarnkha, Leelawadee Techasatian, Suchaorn Saengnipanthkul, Pope Kosalaraksa, Kaewjai Thepsuthammarat, Rattapon Uppala","doi":"10.1016/j.ijid.2026.108766","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108766","url":null,"abstract":"<p><strong>Objectives: </strong>Multisystem inflammatory syndrome in children (MIS-C) is a severe post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inflammatory condition. This study described MIS-C epidemiology and outcomes in Thailand during 2021-2023 and identified predictors of in-hospital death.</p><p><strong>Methods: </strong>A nationwide retrospective cohort study used Thai National Health Security Office (NHSO) inpatient data. Children aged 1 month to <18 years with MIS-C (ICD-10-TM codes U10 and U10.9) were included. Severe manifestations, organ dysfunction, and procedures were identified using ICD-10-TM, and ICD-9-CM codes. Logistic regression was used to evaluate mortality predictors.</p><p><strong>Results: </strong>Among 634 MIS-C hospitalizations (59.2% male; median age 6 years), National incidence peaked at 3.2 per 100,000 in 2022. In-hospital mortality was 3.2% with regional heterogeneity. Severe cardiac manifestations occurred in 37.4% and severe respiratory manifestations in 12.0%. Malignancy (adjusted odds ratio [AOR] 17.13; 95% confidence interval [95% CI] 1.84-159.92) and disseminated intravascular coagulation (DIC) (AOR 14.16; 95% CI 2.10-95.37) independently predicted mortality.</p><p><strong>Conclusions: </strong>MIS-C burden peaked in 2022 with regional variation. Early risk stratification and timely critical care with advanced organ support remains essential to optimize survival.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108766"},"PeriodicalIF":4.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measles resurgence in Bangladesh, 2026: a warning of fragile immunization gains.","authors":"Najmul Haider, Md Zakiul Hassan, Rumi Ahmed Khan","doi":"10.1016/j.ijid.2026.108765","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108765","url":null,"abstract":"","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108765"},"PeriodicalIF":4.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seven years of stool banking: clinical and microbiological insights from the Ghent Stool Bank.","authors":"Hannelore Hamerlinck, Jerina Boelens, Danny De Looze, Anne-Sophie Messiaen, Stien Vandendriessche, Tom Holvoet, Bruno Verhasselt","doi":"10.1016/j.ijid.2026.108744","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108744","url":null,"abstract":"<p><strong>Objectives: </strong>The Ghent Stool Bank (GSB) was founded in 2018 at Ghent University Hospital to provide safe, ready-to-use faecal suspensions for faecal microbiota transplantation (FMT), primarily targeting recurrent Clostridioides difficile infection (rCDI) and supporting clinical trials.</p><p><strong>Methods: </strong>This retrospective cohort study explores the relationship between donor characteristics and rCDI treatment outcomes following FMT.</p><p><strong>Results: </strong>Between 2018 and 2024, 12.0% of screened candidates qualified as donors after rigorous evaluation, resulting in 159 approved donations. Forty-four FMT procedures were carried out in forty rCDI patients, achieving a primary cure rate of 77.1%, which increased to 85.7% following a second treatment. Donor microbiome diversity did not show association with treatment outcomes, and no statistically significant differences in taxa abundance were observed. Notably, faecal suspensions stored for up to five years were as effective as those stored for shorter periods. Additionally higher donor age did not appear to negatively impact treatment success in rCDI patients.</p><p><strong>Conclusion: </strong>These findings support the role of stool banks like the GSB in ensuring safe FMT procedures. Allowing higher donor age and longer storage periods may help sustain sufficient high‑quality donor availability. Future efforts should focus on improving safety, enhancing donor-recipient compatibility through microbiome profiling and increasing public awareness.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108744"},"PeriodicalIF":4.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of onchocerciasis elimination in the Democratic Republic of Congo.","authors":"Jean Claude Makenga Bof","doi":"10.1016/j.ijid.2026.108735","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108735","url":null,"abstract":"<p><strong>Background: </strong>Onchocerciasis remains a major public health problem in the Democratic Republic of Congo (DRC), one of the countries with the highest burden globally. Despite more than two decades of community-directed treatment with ivermectin (CDTI), progress toward elimination has been slower than expected. This review examines the main epidemiological, operational, and governance-related barriers that continue to hinder elimination efforts.</p><p><strong>Methods: </strong>We conducted a structured narrative review informed by World Health Organization (WHO) frameworks for evaluating neglected tropical disease programmes. National programme reports, WHO technical documents, peer-reviewed publications, and grey literature produced between 2001 and 2020 were reviewed. Searches were performed in PubMed, Scopus, and Google Scholar using terms related to onchocerciasis, Onchocerca volvulus, Loa loa, ivermectin, CDTI, elimination, mapping, surveillance, and the DRC. Evidence was triangulated across epidemiological, operational, and governance domains.</p><p><strong>Results: </strong>Major barriers include incomplete elimination mapping, large areas of unknown endemicity, and widespread co-endemicity with Loa loa, which limits the safe implementation of mass drug administration. Additional challenges include difficult terrain, insecurity, limited entomological capacity, programme interruptions, and concerns about sub-optimal ivermectin response. Operational weaknesses such as inadequate therapeutic and geographic coverage, delayed drug delivery, weak supervision, and attrition of community drug distributors further undermine CDTI effectiveness. Governance weaknesses, including delayed fund disbursement and insufficient accountability, also affect programme performance.</p><p><strong>Conclusion: </strong>Achieving elimination in the DRC will require completion of nationwide elimination mapping, strengthened epidemiological and entomological surveillance, improved governance, and financing mechanisms, and tailored strategies for Loa loa co-endemic and conflict-affected settings. Recent WHO guidance on elimination mapping and evolving strategies such as test-and-not-treat and moxidectin may help accelerate progress.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108735"},"PeriodicalIF":4.3,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a four-gene host signature for paucibacillary TB among symptomatic individuals with sputum Xpert MTB/RIF Ultra very low and trace results.","authors":"Kattya Lopez, Robert Reiss, Vaishnavi Kaipilyawar, Arthur VanValkenburg, Xutao Wang, Nisha Modi, Emily Hennig, Aanchal Wats, Christie Eichberg, Lydia Nakiyingi, Chad Centner, Kimberly McCarthy, Jerrold J Ellner, David Alland, Susan E Dorman, W Evan Johnson, Yingda L Xie, Padmini Salgame","doi":"10.1016/j.ijid.2026.108763","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108763","url":null,"abstract":"<p><strong>Objectives: </strong>The Xpert MTB/RIF Ultra (Ultra) assay is widely used to diagnose pulmonary tuberculosis (TB), but 'very low' or 'trace' results may reflect either paucibacillary TB or TB-negative disease, complicating clinical decision-making. We evaluated host transcriptomic signatures to identify culture-confirmed paucibacillary TB among individuals with Ultra very low or trace results.</p><p><strong>Methods: </strong>We performed whole blood targeted transcriptional profiling of 90 symptomatic adults from Uganda, Kenya, and South Africa with Ultra very low/trace sputum results. An 81-gene customized NanoString panel representing 13 published TB signatures was analyzed using machine learning to derive a novel four-gene host signature (\"TRACE4\") predicting MGIT and LJ culture positivity. Validation included individuals with other respiratory diseases (n=18) and North American-TB-negative controls (n=20). Data were randomly split 75/25 into training (n=67) and test (n=23) sets. Diagnostic performance was evaluated against WHO targets.</p><p><strong>Results: </strong>TRACE4 outperformed all published signatures in both training (AUC 0.89) and test sets (AUC 0.88), achieving 82% specificity at 75% sensitivity. It also exceed reclassification based on prior TB history (specificity 0.58 (95% CI: 0.45-0.69); sensitivity 0.35 (95% CI: 0.15-0.61)). TRACE4 showed 100% specificity in non-TB controls.</p><p><strong>Conclusion: </strong>TRACE4 shows promise for identifying paucibacillary culture-positive pulmonary TB in this diagnostically challenging group.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108763"},"PeriodicalIF":4.3,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Early Oral Antiviral Use for Outpatients With COVID-19 on Healthcare Utilization and Recovery (ANCHOR-02).","authors":"Makoto Hibino, Ayumi Shintani, Hiroyuki Murayama, Nobuyuki Morikawa, Hikari Higa, Sho Nishiguchi, Eiji Monma, Bumpachi Kakii, Sadaharu Asami, Hidemitsu Nakagawa, Naoko Kudo, Yohei Maeda, Masahiro Kinoshita, Takahiro Yoden, Yusaku Takahashi, Shinichi Higashiue","doi":"10.1016/j.ijid.2026.108754","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108754","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the associations of early-phase oral antivirals with recovery in outpatients with COVID-19, regardless of baseline risk for severe disease, during the SARS-CoV-2 Omicron JN.1-/KP.3-dominant epidemic era.</p><p><strong>Methods: </strong>This nationwide, multi-institutional (51 acute-care hospitals in Japan), prospective, registry-based cohort study enrolled outpatients aged ≥12 years with laboratory-confirmed COVID-19 within 5 days of symptom onset (February 1-October 31, 2024). Participants were compared between those with and without oral antiviral use at enrollment (ensitrelvir, nirmatrelvir, or molnupiravir) for medical re-consultation, failure to return to usual health, and work productivity and activity impairment through Day 28. Analyses were conducted among participants with complete baseline covariates and valid Day 28 outcome assessments and were adjusted for pre-specified baseline covariates.</p><p><strong>Results: </strong>Baseline characteristics were generally comparable between groups (efficacy analysis population: antiviral n=2271; no antiviral n=5768). Overall re-consultation rates tended to be lower in the antiviral group (adjusted risk ratio [aRR] 0.93; 95% CI 0.83-1.04). Antiviral use was associated with lower rates of failure to return to usual health (aRR 0.76; 95% CI 0.70-0.82) and with improvements in presenteeism, overall work impairment, and activity impairment.</p><p><strong>Conclusions: </strong>Early-phase oral antiviral use was associated with more favorable patient-reported and functional recovery outcomes, with a trend toward reduced healthcare utilization. These findings may have broader societal implications beyond traditional virological and disease progression endpoints.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108754"},"PeriodicalIF":4.3,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive Corticosteroids and Mortality in Non-HIV Patients with Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-Analysis.","authors":"Jiaqi Pu, Shouquan Wu, Jian-Qing He","doi":"10.1016/j.ijid.2026.108761","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108761","url":null,"abstract":"<p><strong>Background: </strong>The role of adjunctive corticosteroids in non-HIV PJP remains controversial.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies comparing adjunctive corticosteroids plus standard antimicrobial therapy versus standard therapy alone in HIV-negative adults with PJP. We searched PubMed, Embase, Web of Science, and Cochrane Library from inception to December 19, 2025. The primary outcome was all-cause mortality. We performed meta-analyses using random-effects models, subgroup analyses by mortality timing, and sensitivity analyses.</p><p><strong>Results: </strong>Twenty studies (one RCT, 19 observational studies) involving 3,816 patients were included. Among 2,899 patients receiving corticosteroids, 756 died (26.1%), compared to 246 deaths among 917 controls (26.8%). The pooled analysis showed no significant association between adjunctive corticosteroids and all-cause mortality (odds ratio [OR] 1.10, 95% confidence interval [CI]: 0.86-1.41; P = 0.43; I² = 21%). Subgroup analyses for short-term (≤30-day) mortality (OR 1.13, 95% CI: 0.78-1.63) and long-term (>30-day) mortality (OR 1.36, 95% CI: 0.79-2.32) also demonstrated no significant benefit. Results were robust in sensitivity analyses.</p><p><strong>Conclusions: </strong>Adjunctive corticosteroids were not associated with reduced mortality in non-HIV PJP. However, the overall certainty of evidence was very low. Based on current evidence, routine corticosteroid use is not supported, and these findings should be interpreted with caution. Future high-quality randomized trials are needed.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108761"},"PeriodicalIF":4.3,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global incidence rates of invasive fusariosis: a systematic review and meta-analysis.","authors":"Abdulmajeed Amin Sarhan, Abduljawad Ramli Saleh, Mohammed Mansour Alsenani, Hamad Mutlaq Radhi, Saud Moataz Alknawy, Mohammed Eldigire Ahmed, John Ossenkopp, Hassan Almarhabi","doi":"10.1016/j.ijid.2026.108760","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108760","url":null,"abstract":"<p><strong>Background: </strong>Invasive fusariosis is an under investigated fungal infection of high clinical importance. This meta-analysis aimed to estimate the global incidence of this condition.</p><p><strong>Methods: </strong>A systematic review was conducted on January 28th, 2026, using PubMed and Web of Science. Articles in English and Spanish were included. There were no limitations on publication date or study type. Review was reported according to PRISMA guidelines and was non-funded. Protocol was pre-registered on OSF (Doi:10.17605/OSF.IO/YMA6G).</p><p><strong>Results: </strong>119 articles with a sample of 2,227,367 patients were included. Incidence was 0.03 cases / 1,000 inpatient admissions, 4.27 cases / 1,000 solid organ transplants, 8.87 cases / 1,000 HSCT recipients, and 5.62 cases / 1,000 patients with hemato-oncological conditions. A higher incidence was reported from Brazil, in contrast to a lower incidence in Italy. Among patient subgroups, incidence was higher in lung transplants compared to other organs and adult patients with hemato-oncological conditions showed a higher incidence compared to pediatrics.</p><p><strong>Conclusion: </strong>This was the first attempt at estimating the global incidence of invasive fusariosis identifying significant differences between patients and countries. The identification of specific patients at higher risk should enable clinicians to preemptively emblement prophylactic measures, screening tests, and early treatment approaches for this critical condition.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108760"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP/VAP in China: a retrospective real-world multicenter cohort study.","authors":"Huangdu Hu, Yifeng Luo, Meijun Song, Xiaoju Zhang, Min He, Xiangyan Liu, Chun Pan, Lingai Pan, Xiaojing Li, Xianyao Wan, Kun Chen, Wei Cui, Shiting Zhou, Shutao Zou, Jintao He, Haiyang Liu, Xiaoting Hua, Xiaoxing Du, Xi Li, Zhenguo Zeng, Yunsong Yu","doi":"10.1016/j.ijid.2026.108758","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108758","url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major cause of hospital- and ventilator-associated pneumonia (HAP/VAP) with limited treatment options. Eravacycline (ERA) shows potent in vitro activity and favorable pulmonary pharmacokinetics, but clinical evidence for CRAB HAP/VAP remains scarce. We evaluated the real-world effectiveness and safety of ERA.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter cohort study at 12 hospitals in China (April 2022-March 2024). Adults with microbiologically confirmed CRAB HAP/VAP treated with ERA or best available therapy (BAT) for ≥ 4 days were propensity scores matched. Primary outcomes were clinical success at end of treatment (EOT) and 28-day mortality.</p><p><strong>Results: </strong>After 3349 patients screened, 382 were included (ERA 204; BAT 178). Baseline characteristics were balanced. Clinical success at EOT was higher with ERA than BAT (63.2% vs 55.1%), while 28-day mortality was similar (40.1% vs 42.0%). ERA achieved higher microbiological eradication at EOT (45.1% vs 32.0%) and day 14 (36.8% vs 22.5%). Adverse events occurred less frequently with ERA. In targeted first-line treatment, ERA showed higher clinical success, greater microbiological eradication and faster clinical response without increased mortality.</p><p><strong>Conclusion: </strong>Eravacycline improved microbiological clearance, clinical response, and safety compared with BAT for CRAB HAP/VAP, particularly when used as targeted first-line therapy.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108758"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of RSV bronchiolitis in infants with maternal immunization or monoclonal antibodies for the newborn: What do women choose?","authors":"Salomé Azeroual, Domenico Benvenuto, Antoine Perrin, Paul Rey, Odile Launay, Caroline Charlier, Olivia Anselem","doi":"10.1016/j.ijid.2026.108753","DOIUrl":"https://doi.org/10.1016/j.ijid.2026.108753","url":null,"abstract":"<p><strong>Introduction: </strong>Maternal vaccination against RSV and nirsevimab administered to the newborn are the two strategies equally recommended in France for preventing lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants. Data about their respective uptake and factors influencing mother's choice are still lacking.</p><p><strong>Methods: </strong>We conducted a survey through an anonymous self-administered questionnaire that was proposed during post-partum hospitalization to all mothers who gave birth in January 2025 in a French university hospital maternity ward. We collected data to assess the respective administration rates of both methods and analysed reasons underlying women's choice : prior knowledge of RSV prevention, information received during pregnancy, and factors associated with the choice of each preventive strategy.</p><p><strong>Results: </strong>Of the 401 mothers eligible during the survey period, 274 were included. In all, 73.7% (202/274) chose maternal vaccination, 19.3% (53/274) chose nirsevimab and 6.9% (19/274) did not choose any prevention. Mothers who opted for maternal vaccination (n=202) stated that their choice was guided by immediate protection at birth (81.2%), the absence of injection for their newborn (60.4%) and the advice of their gynaecologist or midwife (49.5%). Mothers who opted for nirsevimab (n=53) stated that their choice was guided by the lack of long-term safety data on the vaccine (39.6%) and fear of vaccine adverse effects (35.8%).</p><p><strong>Conclusion: </strong>Within one year of its introduction in France, maternal RSV vaccination was the predominant chosen strategy for preventing bronchiolitis in this study population. This is likely due to the preventive advice they received from healthcare professionals, as well as their desire to avoid an injection for their newborn.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108753"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}